ALK-001 — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-06-30 in 8d
ESTIMATED |
READOUT
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
Phase 2 · Stargardt Disease, Stargardt Macular Degeneration |
Alkeus Pharmaceuticals, Inc. | ALK-001 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|